Phase II Evaluation Of Paclitaxel, Cisplatin And 5-Fluorouracil Given In Combination With Radiation Therapy Prior To Surgery In Patients With Resectable Esophageal Cancer
- Determine the median and two-year disease-free and overall survival of patients with
resectable esophageal cancer treated with neoadjuvant paclitaxel, cisplatin, and
fluorouracil with concurrent radiotherapy.
- Determine the complete and partial responses in patients treated with this regimen.
- Assess the toxicity of this regimen in these patients.
- Determine the optimal dose of paclitaxel when administered in this regimen in these
- Determine the effect of tumor tubulin isoform expression on chemosensitivity and
overall survival of patients treated with this regimen.
OUTLINE: Patients receive paclitaxel IV over 3 hours and cisplatin IV over 1 hour on day 1.
Treatment repeats every 3 weeks for 2 courses.
Beginning 3 weeks after completion of initial chemotherapy, patients receive concurrent
chemoradiotherapy comprising paclitaxel IV over 1 hour and cisplatin IV over 1 hour on days
1, 8, 15, 22, and 29; fluorouracil IV continuously for 5 weeks; and radiotherapy daily 5
days a week for 5 weeks.
At 4-8 weeks after completion of chemoradiotherapy, patients may undergo surgical resection.
Patients with local progressive disease after 2 courses of initial chemotherapy undergo
surgical resection instead of receiving concurrent chemoradiotherapy.
Patients are followed within 6 weeks, every 3 months for 3 years, and then annually for 2
PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study.
Primary Purpose: Treatment
Jonathan Cheng, MD
Fox Chase Cancer Center
United States: Federal Government
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|